2019 Full Year Results: Continued growth from in-house innovation; Revenue doubled in last five years

          September 2019

          Long-term plan announced, incorporating investment to achieve revenue of £450-500m by FY24

          Cambridge, UK: Abcam (AIM: ABC, “Abcam” or “The Group”), a global leader in the supply of life science research tools, today announces its preliminary results for the 12 months ended 30 June 2019.

          FINANCIAL HIGHLIGHTS

          • Total revenue up 11.4% on a reported basis and 9.2% on a constant exchange rate (CER) basis
          • Gross margin up 60 basis points to 70.5%, benefiting from an increasing mix of in-house products
          • EBITDA margin of 32.4% (2017/18: 35.0%), with Adjusted EBITDA margin of 35.6% (2017/18: 37.9%), reflect planned strategic investments in the business
          • Operating profit margin of 21.6% (2017/18: 29.5%), after a £12.8m non-cash impairment charge relating to historic Enterprise Resource Planning (ERP) development costs. Adjusted operating profit margin of 32.2% (2017/18: 34.9%)
          • Reported PBT declined to £56.4m (2017/18: £69.1m). Adjusted PBT grew 2.8% to £83.9m
          • Reported diluted EPS was 21.8p whilst adjusted diluted EPS grew 0.6% to 32.6p
          • Net cash inflow from operating activities of £70.2m (2017/18: £63.3m)
          • Proposed final dividend of 8.58p (2017/18: 8.58p), taking the proposed total annual dividend to 12.13 pence per share, an increase of 1.1%

          OPERATIONAL HIGHLIGHTS

          • All product categories growing above underlying market rates and all strategic performance targets achieved:
            – Recombinant antibody revenue growth (CER) of +22.4% (target 20%+)
            – Immunoassay product revenue growth (CER) of +21.9% (target 20%+)
            – 12-month rolling transactional Net Promotor Score (tNPS) of 59%3 (target 57-67%)
          • Continued in-house innovation, with in-house product revenue growth of 13.6% (CER) and the introduction of the Group’s 18,000th recombinant antibody
          • Further enhancements made to product quality through knockout validation, recombinant antibodies, and other initiatives to improve quality
          • Ongoing development of our addressable market in Custom Products and Licensing (CP&L), with 57 new agreements entered into with biopharmaceutical and diagnostic partners and over 160 custom projects completed during the year
          • Implemented the financial and non-stock procurement modules of our global ERP system
          • Successfully relocated to our new global headquarters in Cambridge, UK

          Alan Hirzel, Abcam’s Chief Executive Officer, said:

          “Our dedication to customer needs, team performance and our long-term investment perspective has helped Abcam to achieve sustained growth and expand its reach and influence over the last five years. Today, we are in a better position than ever before to pursue opportunities to continue to invest in, build and grow a successful global company.”

          “We are reassured that there is more to do and excited about the future prospects for our industry and our business. We are eager to enter a new phase of growth in the coming five years to extend further our impact on research discovery and clinical applications to improve patient lives”

          ##Ends##

          Read the full release

          About Abcam

          Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

          Read more +

          Abcam Products

          As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

          Read more +

          Investor Information

          Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

          Read more +

          Abcam News

          We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

          Read more +
          四虎影院在线观看